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Abstract
Excessive hepatic glucose production is a hallmark of insulin resistance in type 2 diabetes. The cAMP-
responsive transcription factor cAMP-responsive element binding protein (CREB), thought to be a key
activator of the hepatic gluconeogenic gene regulation program, has been suggested as therapeutic target to
reduce glucose output by the liver. Here, I test directly the requirement for hepatocytic CREB for the
maintenance of glucose homeostasis utilizing Cre-loxP for conditional, cell-type specific gene ablation.
Strikingly, I find no difference in fed and fasted glucose levels, or glucose, insulin, and glucagon tolerance in
mice fed normal chow or a high-fat diet in hepatocyte Creb-null mice compared to controls. In addition,
mRNA levels of liver specific genes, including several CREB target genes involved in gluconeogenesis, were
not affected by CREB deficiency in the liver. In conclusion, my data indicate that CREB has no non-
redundant functions in hepatic glucose metabolism, and is therefore not likely to be a useful target for the
development of anti-diabetic drugs.
Furthermore, lipolysis and thermogenesis are regulated by catecholamines signaling via β-adrenergic
receptors in adipose tissue and a role for the CREB in adipocyte function had been suggest by previous
studies. However the role of CREB in adipose tissue had never been evaluated in vivo. Here, I test directly the
requirement for adipocyte CREB for lipolysis and thermogenesis using the Cre-loxP system for adipocyte-
specific ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate decrease in fasting-induced
lipolysis in adipose tissue. Strikingly, the adipocytic transcriptome was not globally affected by ablation of
Creb. In addition, cold temperature and cAMP signaling-induced thermogenesis and white-to-beige
adipocyte conversion were not changed in adipocyte specific Creb-null mice compared to controls. In
conclusion, my data indicate that CREB has no non-redundant functions in thermogenesis, but contributes to
the regulation of fasting-induced lipolysis. The underlying mechanism of reduced fasting-induced lipolysis in
adipocytic CREB-deficient mice will need to be explored further.
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ABSTRACT 
 
THE ROLE OF CREB IN THE LIVER AND ADIPOSE 
TISSUE 
Dolim Lee 
Klaus H. Kaestner 
 
Excessive hepatic glucose production is a hallmark of insulin resistance in type 2 
diabetes.  The cAMP-responsive transcription factor cAMP-responsive element binding 
protein (CREB), thought to be a key activator of the hepatic gluconeogenic gene 
regulation program, has been suggested as therapeutic target to reduce glucose output by 
the liver.  Here, I test directly the requirement for hepatocytic CREB for the maintenance 
of glucose homeostasis utilizing Cre-loxP for conditional, cell-type specific gene 
ablation. Strikingly, I find no difference in fed and fasted glucose levels, or glucose, 
insulin, and glucagon tolerance in mice fed normal chow or a high-fat diet in hepatocyte 
Creb-null mice compared to controls.  In addition, mRNA levels of liver specific genes, 
including several CREB target genes involved in gluconeogenesis, were not affected by 
CREB deficiency in the liver. In conclusion, my data indicate that CREB has no non-
redundant functions in hepatic glucose metabolism, and is therefore not likely to be a 
useful target for the development of anti-diabetic drugs. 
Furthermore, lipolysis and thermogenesis are regulated by catecholamines 
signaling via β-adrenergic receptors in adipose tissue and a role for the CREB in 
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adipocyte function had been suggest by previous studies. However the role of CREB in 
adipose tissue had never been evaluated in vivo. Here, I test directly the requirement for 
adipocyte CREB for lipolysis and thermogenesis using the Cre-loxP system for 
adipocyte-specific ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate 
decrease in fasting-induced lipolysis in adipose tissue. Strikingly, the adipocytic 
transcriptome was not globally affected by ablation of Creb. In addition, cold temperature 
and cAMP signaling-induced thermogenesis and white-to-beige adipocyte conversion 
were not changed in adipocyte specific Creb-null mice compared to controls. In 
conclusion, my data indicate that CREB has no non-redundant functions in 
thermogenesis, but contributes to the regulation of fasting-induced lipolysis. The 
underlying mechanism of reduced fasting-induced lipolysis in adipocytic CREB-deficient 
mice will need to be explored further. 
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CHAPTER 1: General Introduction 
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1.1 Fuel Metabolism and Metabolic Organs 
 
Keeping a tight balance between energy intake and expenditure is critical for all 
living organisms. Disturbances in energy homeostasis lead to metabolic disorders such as 
obesity, metabolic syndrome, and diabetes. Increase in the prevalence of obesity and 
diabetes is a significant public health concern, and its patient population is projected to 
grow faster than ever. In the U.S., currently more than two-thirds of adults are considered 
obese or overweight (NIDDK), and one out of every 11 people have diabetes (CDC).  
Mammals have evolved to efficiently convert food into energy that can be utilized by 
individual cells, and to store excess energy for future use. In a healthy individual, each 
digestive, endocrine, and exocrine organ serves a unique role in metabolism, and the 
finely tuned feedback pathways between the organs ensures that blood glucose levels are 
maintained near 4.5mM, despite constant fluctuations in dietary intake and energy 
expenditure. 
 
1.1.1 Small Intestine 
During a meal, dietary nutrients are enzymatically digested and absorbed in the 
small intestine. Some of digestive enzymes, such as disaccharidases, are secreted from 
intestinal epithelial cells, while others, such as trypsin, elastase and lipases, are produced 
in other organs, such as the pancreas, and transported to the small intestine. The liver also 
plays an important role in the digestive process by producing bile, which solubilizes 
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triglycerides in the diet. The lumen of the small intestine is lined with small finger-like 
projections called villi, which increase the surface area available for absorption. Villi are 
covered with a single layer of epithelial cells; most of which are absorptive cells, with 
some goblet cells and enteroendocrine cells secreting mucus and gastrointestinal 
hormones, respectively. At the base of each villi, there are glandular crypts that contain 
replicating stem cells and paneth cells.  
Dietary proteins are broken down into small peptides and amino acids by 
proteolytic enzymes for absorption. Since only carbohydrate monomers can be absorbed 
by the intestinal epithelium, complex carbohydrates are broken down into simple sugars, 
such as glucose. Dietary lipids are degraded into fatty acids and glycerol by lipase, and 
subsequently are absorbed by villi.  
 
1.1.2 The Pancreas 
The pancreas serves as both an endocrine and exocrine organ.  The islets of 
Langerhans are the endocrine part of the pancreas that secretes hormones, but make up 
only 1-2% of pancreas mass. There are four types of cells in the islets of an adult 
pancreas: α cells, β cells, δ cells, and polypeptide cells. During fasting, glucagon secreted 
from α cells binds glucagon receptors on the surface of hepatocytes and promote hepatic 
glucose production. In addition, glucagon increases triglyceride mobilization by 
stimulating lipolysis in adipose tissue. Glucagon signaling also increases fatty acid 
oxidation, allowing the use of lipid as an energy source, in all tissues except in the central 
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nervous system. When blood glucose levels rise after a meal, β cells secrete insulin, 
which promotes uptake and storage of glucose by the liver, skeletal muscles, and adipose 
tissue.  Also insulin increases fatty acid and triglyceride synthesis in the liver, and they 
are packaged into very low-density lipoproteins and transported to adipose tissue. In the 
adipose tissue very low-density lipoproteins are metabolized, and lipids are stored in 
adipocytes. Opposing actions of glucagon and insulin keep blood glucose levels within a 
constant range. Somatostatin secreted from δ cells is responsible for fine-tuning of 
hormone secretion by α and β cells. Polypeptide cells secrete pancreatic polypeptides that 
regulate pancreatic endocrine and exocrine secretions.  
The exocrine pancreas makes up ≥90% of the total pancreas. It is composed of 
acinar cells connected to small ducts that drain into the pancreatic ductal tree, which in 
turn drain into the main pancreatic duct. Cells in the exocrine pancreas produce digestive 
enzymes, enzyme precursors (zymogens), and bicarbonate, which make up pancreatic 
juice. Pancreatic juice collected in pancreatic duct is released into the duodenum, the first 
section of the small intestine. 
 
1.1.3 The Liver 
The liver is a central metabolic organ, and is responsible for processing and 
distributing nutrients to extrahepatic tissues, including the brain. It also is important in 
detoxification and synthesis of serum proteins. The liver is the first organ that receives 
the nutrients absorbed by small intestine during a meal. Hepatocytes make up about 80% 
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of the total liver mass, and are involved in carbohydrate metabolism, protein metabolism 
and synthesis, and lipid processing and distribution. 
The liver adapts to changes in blood glucose levels to maintain glucose 
homeostasis as depicted in Figure 1.1. Upon receiving the insulin signal, excess glucose 
received during a meal is converted into glycogen via glycogenesis, and stored for later 
use. When blood glucose levels drop, i.e. during fasting, glucagon activates 
glycogenolysis in hepatocytes, and glucose is released into bloodstream to be utilized by 
other cells in the body.  When the glycogen stores are depleted, the liver, and also 
skeletal muscles, activates gluconeogenesis to produce glucose from non-carbohydrate 
precursors, such as lactate, glycerol, alanine and glutamate, to meet glucose demand.  
Diet-derived lipids are packaged into chylomicrons by small intestinal epithelial 
cells and transported to the liver.  The liver processes fatty acids into phospholipids and 
triacylglycerol to form very low-density lipoproteins, to be transported to adipose tissue 
for storage. Within hepatocytes, fatty acids can also serve as substrate for oxidation to 
produce energy, cholesterol, and ketone bodies. Furthermore, when excess carbohydrate 
is available, the liver converts carbohydrate into fat by de novo lipogenesis. 
Amino acids taken up by the liver can serve as precursors for proteins, hormone 
and nucleotide synthesis.  During fasting, muscle protein is broken down and amino acids 
are released into circulation, and then taken up by the liver. Some of these amino acids 
are used as substrates to produce precursors for gluconeogenesis, while others are use in 
ketogenesis.   
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1.1.4 Adipose Tissue 
White adipose tissue is mainly composed of white adipocytes whose primary role 
is to store lipids. During a meal, glucose can be converted into fatty acids, and then to 
triacylglycerides in adipose tissue for storage. Free fatty acids enter adipocytes, and with 
glycerol, are assembled into triacylglycerides. When there is a demand for more energy, 
epinephrine stimulates triacylglyceride hydrolysis and fatty acids are released into the 
blood stream. 
In rodents and human infants, although to a lesser extent in human adults, non-
shivering thermogenesis occurs in specialized adipose tissue called ‘brown adipose 
tissue’. Brown adipocytes have numerous mitochondria and smaller lipid droplets 
compared to the large, single lipid droplet as in white adipocytes. Heat is generated via 
uncoupling the mitochondrial respiratory chain through expression of high levels of 
uncoupling proteins. 
 
1.2 cAMP Response Element-Binding Protein (CREB) 
 
1.2.1 cAMP Signaling Pathway 
cAMP was the first “second messenger” discovered as a mediator of hormone 
induced glucose production in the liver (Sutherland and Robison 1969; Montminy and 
Bilezikjian 1987) . When ligands bind to cell-surface receptors that are coupled to 
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heterotrimeric GTP binding proteins (G-proteins), the Gα subunit is activated and 
dissociates from GβGγ. There are several different isoforms of the Gα subunit that can 
interact with different effector molecules to carry out biological response to specific 
ligand binding. For instance, upon epinephrine or glucagon signaling, activated Gαs can 
stimulate adenylyl cyclase, an enzyme that converts ATP into cAMP.  
Protein kinase A (PKA) is a cAMP-dependent protein kinase, whose activation is 
regulated by intracellular cAMP levels. In the basal state, PKA is composed of two 
regulatory subunits and two catalytic subunits. Binding of cAMP to regulatory subunits 
causes release of catalytic subunits, allowing their translocation into the nucleus. 
Activated catalytic subunits of PKA can regulate activity of downstream proteins by 
phosphorylating Ser or Thr residues. 
 
1.2.2 CREB mediates cAMP effects on Transcriptional Regulation 
Nearly three decades ago, CREB was discovered as a nuclear protein that binds to 
the cAMP response element (CRE), a conserved promoter element, located in the 
somatostatin gene, and activates its expression in response to increased intracellular 
cAMP levels (Montminy and Bilezikjian 1987). CREs can be either full palindromic 
(TGACGTCA) or half-site (TGACG or CGTCA) sequences, and are often located in 
proximal promoter regions (Zhang et al. 2005; Everett et al. 2013). CREB is a 
ubiquitously expressed DNA binding transcription factor that forms a dimer, and 
structurally belongs to the basic leucine zipper protein family (Hoeffler et al. 1988). 
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There are other family members of CREB, which in addition to CREB are the activating 
transcription factor 1 (ATF1) and cAMP- responsive element modulator (CREM), and 
these two proteins can also mediate transcriptional response to cAMP signaling. CREB 
family members share a conserved dimerization domain and kinase-inducible domain, 
and some functional redundancy exists among them (Hummler et al. 1994). The G 
protein-coupled receptor (GPCR) signaling pathway leading to activation of CREB is 
depicted in Figure 1.2. Upon glucagon or epinephrine signaling, activated PKA 
translocates into the nucleus, and phosphorylates CREB at Ser133 (Gonzalez and 
Montminy 1989). This leads to activation of CREB, and promotes target gene expression 
by recruitment of transcriptional co-activators, such as CREB-binding protein (CBP) and 
p300, and RNA polymerase II complexes to promoters containing CREs. CBP and p300 
have intrinsic histone acetyltransferase activity, which leads to loosening of chromatin 
structure, thus increasing access for RNA polymerase, and results in increased expression 
of downstream genes (Ogryzko et al. 1996). 
More recently, the CREB-regulated transcription coactivator (CRTC), also known 
as transducer of regulated CREB activity (TORC), family of cofactors was discovered 
(Iourgenko et al. 2003). Although DNA binding by CREB does not depend on 
recruitment of CRTC, presence of CRTC has been shown to enhance RNA polymerase II 
interaction (Conkright et al. 2003). In the absence of a cAMP signal, cytoplasmic CRTC 
is sequestered by 14-3-3 proteins, due to phosphorylation at Ser171 by Ser/Thr kinase 2 
(SIK2) (Screaton et al. 2004). Elevation of cytoplasmic cAMP levels leads to inhibition 
of SIK2 and dephosphorylation of CRTC, ultimately resulting in its dissociation from 14-
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3-3 proteins and translocation into the nucleus for interaction with CREB (Screaton et al. 
2004). 
 
1.3 CREB in Glucose Homeostasis 
 
1.3.1 Hepatocytic CREB as the Central Regulator of Gluconeogenesis 
When blood glucose levels are low, glucagon secretion leads to inhibition of 
glycogen producing glycogen synthase and activation of glycogen phosphorylase, a rate-
limiting enzyme involved in breakdown of glycogen into glucose. During prolonged 
fasting, starvation, or following intense exercise, glucose is also generated via 
gluconeogenesis. Gluconeogenesis is essentially a reversal of glycolysis (Figure 1.3). 
Three endergonic steps in glycolysis are catalyzed by three different key enzymes in 
gluconeogenesis: phosphoenolpyruvate carboxykinase (PEPCK), fructose 1, 6-
bisphosphatase (FBPase), and glucose 6-phosphatase (G6Pase) (Figure 1.3).  
Lactate is a major source of carbon atoms for gluconeogenesis. Lactate produced 
by glycolysis in non-hepatic tissues is transported to the liver, and lactate dehydrogenase 
converts lactate into pyruvate, the first designated substrate of gluconeogenesis (Figure 
1.3). All amino acids, except leucine and lysine, can be converted into glucose. During 
hypoglycemia, muscle proteins are broken down into amino acids and transported to the 
liver. Some amino acids are catabolized into pyruvate, oxaloacetate or precursors of these. 
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Glycerol from the breakdown of triacylglycerol in adipose also can be used for 
gluconeogenesis.  
Previous studies suggested CREB as the master regulator of gluconeogenesis in 
the liver. CREs are located in proximal promoter regions of key gluconeogenic genes, 
suggesting direct transcriptional regulation by CREB (Zhang et al. 2005; Everett et al. 
2013). The model suggests that during short-term fasting, glucagon binds to GPCR on the 
surface of hepatocytes, and activated CREB can induce transcription of gluconeogenic 
genes, such as Pepck and G6pase (Montoliu et al. 1994; Herzig et al. 2001; Thiel et al. 
2005) (Figure 1.4). CREB also increases expression of peroxisome proliferator-activated 
receptor- γ (PPAR-γ) coactivator-1α (Pgc-1α), which can also interact with other co-
activators at the transcription start site located in key gluconeogenic genes, further 
activating expression of the gluconeogenic programing during prolonged fasting (Herzig 
et al. 2001) (Figure 1.4). 
 
1.3.2 CREB as a Potential Therapeutic Target for Type 2 Diabetes Mellitus 
(T2DM) 
Type 2 diabetes mellitus is a chronic metabolic disorder marked by 
hyperglycemia, endocrine pancreatic dysfunction, and insulin resistance. T2DM accounts 
for about 90% of all diagnosed cases of diabetes and is a major public health concern as 
the fastest growing disease in the world. According to the CDC, there are currently 25.8 
million Americans with diabetes, comprising 8.3% of the U.S. population. In 2010, 
diabetes was the 7th leading cause of death in the U.S. (CDC). This is likely to be an 
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underestimate, since failure to maintain glucose homeostasis contributes to other 
detrimental complications such as cardiovascular disease, blindness, hepatic steatosis, 
and kidney failure. Elevated hepatic gluconeogenesis, caused by increased glucagon 
levels, decreased insulin secretion, and insulin resistance, is the major contributor to 
fasting hyperglycemia in type 2 diabetic patients (Magnusson et al. 1992; Gastaldelli et al. 
2000). There are three different types of drugs for T2DM: ones that help pancreatic 
insulin secretion, ones enhance insulin sensitivity in peripheral tissue, and others that 
limit excess glucose output from the liver. Although many advances have been made in 
type 2 diabetes treatments, there are still safety and tolerability issues. With the expected 
increase in the diabetic patient population and cost associated with the disease, there is a 
strong need for development of a new class of drugs. 
As the major mediator of cAMP effects on transcription of gluconeogenic genes 
in the liver, CREB has been suggested as a potential drug target to reduce hyperglycemia 
and hepatic insulin resistance in T2DM patients. To understand the effect of CREB 
inhibition on glucose homeostasis, a dominant-negative inhibitor of CREB, A-CREB, 
was utilized in many studies. A-CREB contains an acidic amphipathic protein sequence 
that replaces the CREB basic region connected to the N-terminus of the dimerization 
domain (Ahn et al. 1998). A-CREB forms a heterodimer with endogenous CREB protein 
and prevents CREB from binding DNA. Expression of A-CREB via systemic injection of 
adenovirus expressing A-CREB leads to a decrease in fasting glucose levels compared to 
that of control, accompanied by a 4-fold decrease in expression levels of Pepck and 
G6pase  (Herzig et al. 2001). Also, overexpression of A-CREB was able to lower blood 
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glucose levels of db/db mice to a normal range by lowering Pepck and Pgc1α mRNA 
levels (Herzig et al. 2001). In a separate study, in order to induce tissue-specific reduction 
of Creb expression, antisense oligonucleotide (ASO) was also utilized. Similar to the A-
CREB study, improvements in fasting glucose levels and lower gluconeogenic gene 
expression levels were observed when hepatic and adipocytic Creb expression levels 
were reduced by ASO in the rodent models of insulin resistance and obesity (Erion et al. 
2009).  Together, these results suggest CREB as a novel therapeutic target to lowering 
blood glucose levels in T2DM patients by inhibiting excess gluconeogenesis in the liver.  
However, despite both approaches leading to reduction of blood glucose levels, 
they exhibited a contradicting hepatic lipid phenotype. Inhibition of CREB by A-CREB 
lead to increased expression levels of lipogenic genes, such as Cd36, Fas, Acl, and Srebp, 
with development of a fatty liver phenotype (Herzig et al. 2003). On the other hand, 
Erion and colleagues found that CREB ASO alleviated fatty liver by reducing hepatic 
triacylglycerol content and lowering lipogenic gene expression levels (Erion et al. 2009). 
Fatty liver is commonly observed in type 2 diabetes patients, and although conditions 
itself can be reversible; it can develop into detrimental conditions such as liver cirrhosis 
and liver cancer, if left untreated. Thus this disagreement in the fatty liver phenotype 
poses a serious threat in developing drugs against CREB. 
Contradicting phenotypes from these studies could be explained in part by the 
limitations of approaches taken. In the A-CREB study, expression of A-CREB was under 
the control of the cytomegalovirus (CMV) promoter.  Thus it is difficult to determine if 
the lower blood glucose levels seen in A-CREB expressing mice were exclusively due to 
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the inhibition of CREB activity in the liver. Furthermore, there is a possibility that some 
observed phenotypes resulted from A-CREB interacting with other basic leucine zipper 
proteins, including other CREB family members (Ahn et al. 1998).  Similarly, CREB-
ASO treatment affected Creb mRNA levels in both liver and white adipose tissue, which 
makes it hard to determine if inhibition of hepatic, adipocytic CREB or combination of 
both is required for the improvement of insulin sensitivity. In addition, there are potential 
off-target effects by ASO. Therefore, there is a need for proper reevaluation of the current 
understanding of CREB’s role in glucose homeostasis, to determine whether it could be 
the next therapeutic target for T2DM. 
 
1.4 Adipose Tissue Biology and Function 
 
1.4.1 White and Brown Adipocytes 
Despite their initial origin from pluripotent mesenchymal stem cells (MSCs), 
white and brown adipocytes come from different precursor cells. Indeed, brown 
adipocytes originate from myogenic factor 5 (myf5) and paired-box 7 (pax7) positive 
precursors, which also give rise to myocytes (Hasty et al. 1993; Seale et al. 2008). The 
differences between white and brown adipocytes are highlighted further by functions they 
serve. As mentioned earlier, the main role of white adipose tissue (WAT) is to store 
excess energy in a form of lipid droplets. Storage and utilization of lipids allows 
adaptation to different energy needs throughout the day. Furthermore, WAT acts as an 
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endocrine organ, producing and secreting protein hormones. These adipose-derived 
hormones, adipokines, can influence inflammation (Bruun et al. 2001) and energy 
metabolism (Hu et al. 1996; Halaas et al. 1997; Steppan et al. 2001). Unlike WAT, brown 
adipose tissue (BAT) mainly functions in thermogenesis. White and brown adipocytes 
have distinctive morphology that best serves their function. White adipocytes are mostly 
made of a large single lipid droplet with its nucleus pushed to periphery. In contrast, 
brown adipocytes contains multiple, small lipid droplets and numerous mitochondria, 
which gives it a brown hue. 
 
1.4.2 Lipolysis 
Upon increased energy demand, triacylglycerol is catabolized to generate non-
esterified fatty acids (NEFAs) via lipolysis from adipocytes. Lipolysis can be induced by 
several hormones; such as glucagon (Blecher et al. 1969; Exton et al. 1972), epinephrine 
(Blecher et al. 1969; Exton et al. 1972), norepinephrine, growth hormone (Dietz and 
Schwartz 1991), adrenocorticotropic hormone (Blecher et al. 1969), and thyroid-
stimulating hormone (Goodman and Bray 1966; Gagnon et al. 2010). Binding of these 
hormones to GPCRs leads to activation of the cAMP signaling pathway, and activation of 
lipolytic enzymes. During lipolysis, triacylglycerol is initially hydrolyzed into 
diacylglycerols and NEFAs by adipose triglyceride lipase (ATGL) (Zimmermann et al. 
2004). Hormone-sensitive lipase (HSL) is the rate-limiting enzyme of diacylglycerol 
hydrolysis that produces monoacylglycerol and NEFAs (Osuga et al. 2000; Haemmerle et 
al. 2002). HSL is also capable of hydrolyzing other acylesters like triacylglycerol, 
	  	  15 
monoacylglycerol, cholesteryl esters, and retinyl esters. As the name suggests, lipolytic 
hormone signaling leads to phosphorylation of HSL by PKA, and activated HSL 
translocates to the lipid droplet (Clifford et al. 2000). Lastly, monoglyceride lipase (MGL) 
breaks down monoacylglycerol into glycerol and NEFAs (Karlsson et al. 1997). NEFAs 
and glycerol produced during lipolysis are delivered to peripheral tissues for energy 
production. 
 
1.4.3 Thermogenesis and Energy Expenditure 
BAT is a major site of non-shivering thermogenesis in many mammals.  
Uncoupling protein-1 (UCP1) in the inner membrane of brown adipocyte mitochondria 
decreases the proton gradient, and uncouples oxidative phosphorylation, leading to heat 
generation. Thermogenesis is regulated mainly by the sympathetic nervous system 
through norepinephrine signaling (Landsberg et al. 1984). Β3-adrenergic receptors are 
mainly found in white and brown adipose tissue and regulate lipolysis and thermogenesis. 
Norepinephrine binds Β3-adrenergic receptors on brown adipocytes, and the cAMP 
signaling is induced downstream (Cannon et al. 1996). A rise in intracellular levels 
activates PKA, which phosphorylates a series of target enzymes that stimulates 
expression and activation of UCP1. PGC1α is coactivator of adaptive thermogenesis, and 
enhance transcription of Ucp1 (Puigserver et al. 1998; Wu et al. 1999). Also, lipolysis is 
induced by activation of HSL and deactivation of perillipin that releases glycerol and free 
fatty acids from lipid droplets. Fatty acids serve as both activators of UCP1 and 
substrates for oxidative phosphorylation (Figure 1.5).   
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 It has been demonstrated that thermogenesis can be also activated by food intake 
as well as cold exposure, linking energy expenditure and thermogenesis (Rothwell and 
Stock 1979; Rothwell et al. 1982). Thus, there is interest in BAT as a potential anti-
obesity target, since thermogenesis burns and ‘wastes’ large amounts of lipids and 
glucose (Lockie et al. 2013; Mund and Frishman 2013; Chechi et al. 2014). Defective 
thermogenesis is shown to be associated with obesity in rodent models of genetic obesity 
and T2DM, due to deficits in energy expenditure (Trayhurn and James 1978; Trayhurn 
1979; Hogan and Himms-Hagen 1980; Trayhurn and Fuller 1980). In humans, presence 
of BAT in adults has only been recognized recently (Hany et al. 2002; Yeung et al. 2003). 
Some studies have indicated an inverse correlation between body mass index and BAT 
activity (Cypess et al. 2009; Saito et al. 2009; van Marken Lichtenbelt et al. 2009). 
Therefore BAT activity can potentially contribute to energy expenditure in adult humans.  
 
1.4.4 Beige Adipocytes 
More recently, another class of adipocytes called beige (brite) adipocyte was 
discovered. Beige adipocytes are subset of traditional white adipocytes transformed to 
express UCP1 after cold stimulation or chronic treatment with agonists that elevate 
intracellular cAMP levels (Young et al. 1984; Cousin et al. 1992; Ghorbani et al. 1997; 
Ghorbani and Himms-Hagen 1997; Petrovic et al. 2010). In rodents, beige adipocytes 
mostly arise from the inguinal WAT (Vitali et al. 2012). Although these beige adipocytes 
are similar to white adipocytes in the basal state with low expression of thermogenic gene 
program, cAMP stimulation increases expression of thermogenic genes including Ucp1 at 
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levels similar to those in brown adipocytes, suggesting thermogenic ability (Wu et al. 
2012). Molecular characteristics of human brown adipocytes are similar to that of murine 
beige adipocytes rather than brown adipocytes (Wu et al. 2006). Thus simulants that 
induce ‘browning’ of white adipose tissue may be useful in treating obesity and diabetes 
in humans. 
 
1.4.5 CREB in Adipose Tissue 
 In previous study, obese mice expressing a dominant-negative CREB in 
adipocytes displayed improved insulin sensitivity and were protected from adipose tissue 
inflammation (Qi et al. 2009). In addition, CREB-regulated transcription coactivator 3 
(CRTC3) was shown to promote obesity by attenuating β-adrenergic receptor signaling in 
adipose tissue (Song et al. 2010). These studies suggest that adipocytic CREB plays an 
important role in energy homeostasis. 
In brown adipocytes, CREB can be activated by both classical β3- adrenergic/PKA 
and α1-adrenergic/protein kinase C pathway (Chaudhry and Granneman 1999; Thonberg 
et al. 2002). Thermogenesis is under positive adrenergic control and it is possible for 
CREB to mediate expression of key genes involved in thermogenesis, including Ucp1. 
Proximal promoter regions of the mouse Ucp1 gene contain half-CREs along with other 
cis-regulatory elements such as peroxisome proliferator-activated receptor response 
elements (PPREs) and thyroid response elements (TREs) (Kozak et al. 1994; Rim and 
Kozak 2002). Cold-stimulated UCP1 levels in beige adipocytes were higher in the A/J 
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strain of mice compared to that of the obesity-prone C57BL/6J strain, and coincided with 
higher activation of CREB (Xue et al. 2005).  Furthermore, CREB was found to form a 
heterodimer with CCAAT/enhancer-binding protein beta (C/EBPβ), and regulate cAMP-
induced expression of Pgc1α in adipocytes which also plays a role in cold-induced 
thermogenesis by regulating Ucp1 expression (Karamanlidis et al. 2007; Karamitri et al. 
2009). Despite these studies implying potential regulation of thermogenesis by CREB, 
the role of CREB in adipocytes has never been investigated directly.  
 
1.5 Hypothesis and Objectives 
The liver is the central regulator of glucose homeostasis. It quickly adapts to 
changes in energy demand of the body, storing excess glucose during feeding and 
producing glucose via glycogenolysis and gluconeogenesis during fasting and intense 
physical activity. In T2DM patients, increased hepatic glucose output is the major cause 
of hyperglycemia. CREB has been established as the central regulator of gluconeogenesis 
(Herzig et al. 2001; Erion et al. 2009), implying it as an attractive therapeutic target to 
reduce blood glucose levels. Based on previous studies, loss of hepatic CREB is expected 
to reduce circulating glucose levels due to decreased gluconeogenesis. To address this 
hypothesis, in Chapter 3, I evaluate glucose homeostasis and insulin sensitivity in mice 
with hepatocytic ablation of CREB, and reveal that CREB has no non-redundant function 
in hepatic regulation of glucose homeostasis, which disproves conventional 
understanding of CREB’s role as the master regulator gluconeogenesis (Herzig et al. 
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2001; Erion et al. 2009).  This work provides definitive understanding of the role of 
CREB in the liver, and helps determining whether CREB is a useful therapeutic target. 
Adipose tissue is a dynamic organ actively involved in regulation of energy 
expenditure. Lipolysis and thermogenesis are under the control of adrenergic signaling 
coupled to the cAMP-signaling pathway. As one of the major effectors of cAMP on 
transcriptional regulation, I hypothesize that CREB is involved in activation of 
thermogenesis and white-to-beige adipocyte transformation via regulation of Ucp1 
expression. In Chapter 4, I investigate the role of CREB in adipose tissue in regulation of 
thermogenesis and beige adipocyte formation. This work investigates CREB in 
thermogenesis, which has been stipulated but never tested before. 
 
 
 
 
 
	  	  20 
 
Figure 1.1: Hepatic Glucose Metabolism 
The liver responds to glucagon and insulin signaling and adapts to different blood 
glucose levels. Excess glucose is stored in the liver in the form of glycogen. When 
needed, glucose can be released from glycogen stores or produced from non-carbohydrate 
precursor. 
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Figure 1.2: Activation of CREB via cAMP signaling 
In a basal state, inactive CREB is bound to CREs near the transcription start site of target 
genes. Binding of agonist to GPCRs lead to increase in intracellular cAMP levels. 
cAMPs can activate PKA, and its catalytic subunits translocate to the nucleus. CREB is 
activated when PKA phosphorylates Ser133 on CREB, inducing transcription. 
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Figure 1.3: Glycolysis and Gluconeogenesis 
Gluconeogenesis is essentially a reversal of glycolysis. Three key gluconeogenic 
enzymes that bypass endergonic reactions are highlighted with stars. 
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Figure 1.4: Model of proposed transcriptional regulation of gluconeogenic genes by 
CREB 
 from (Altarejos and Montminy 2011). During short-term fasting, CREB stimulates 
transcription of Pgc1α and members of the nuclear receptor subfamily 4 group A (Nr4a) 
family of orphan nuclear receptors, in addition to key gluconeogenic genes. During 
prolonged fasting, PGC1α and NR4A1 can further induce gluconeogenesis by interacting 
with other transcription factors or directly binding to cis-regulatory regions of 
gluconeogenic genes. 
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Figure 1.5: Thermogenesis 
from (Klaus 2001). Norepinephrine activates cAMP signaling via β-adrenergic receptors. 
PKA activates HSL via phosphorylation, and triacylglycerols are hydrolyzed to produce 
glycerol and fatty acids. Fatty acids are substrates for oxidative phosphorylation. In 
addition, fatty acids can also activate UCP1, which mediates heat generation by 
uncoupling respiratory chain. 
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CHAPTER 2: Materials and Methods 
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Animals 
For the derivation of CrebloxP mice, a 12kb DNA fragment containing exon 11 of 
the Creb gene was retrieved from C57BL/6J mouse BAC clone RP23-31C24 via bacterial 
recombination. One loxP site was inserted upstream of exon 11, while a pair of loxP sites 
flanking a neomycin selection cassette was placed downstream of exon 11.  The 
linearized targeting vector was electroporated into B6 ES cells (Chemicon) and clones 
surviving selection were screened for homologous recombination by Southern blot 
analysis.  Targeted clones were injected into C57BL/6J-derived blastocysts that were then 
transferred to pseudo-pregnant females.  Male offspring were mated to C57BL/6J females 
and ES cell-derived offspring were identified by PCR-based genotyping.  Mice harboring 
the targeted insertion of the three loxP sites in the Creb locus were crossed to the EIIa-
Cre line to achieve mosaic germ line deletion of loxP-flanked sequences. The derivation 
of the CrebloxP was performed by Dr. John Le Lay. 
For liver-specific deletion of the CrebloxP alleles, CrebloxP/loxP mice were 
anaesthetized with isoflurane and injected with adeno-associated virus expressing Cre-
recombinase under the control of the thyroxine-binding globulin (Tbg) promoter (AAV-
Cre). Homozygous mice injected with virus expressing GFP (AAV-GFP) were used as 
controls. Adeno-associated virus are generated by the Penn Vector Core. The expression 
of GFP or Cre in wild-type livers using this viral delivery system did not result in any 
detectable changes in carbohydrate or lipid metabolism. Normal mouse-chow diet (5015; 
Purina Mills) fed mice were injected with adeno-associated virus at 8 to 10 weeks of age. 
A cohort of mice was started on high fat diet (60% kcal from fat; D12492; Research 
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Diets) upon weaning. Mice fed a high fat diet were injected with adeno-associated virus 
at 12 to 14 weeks of age. All mice are given virus injection of 2 x 1011 genomic copies 
per mouse. Experiments were performed two weeks after virus injection to ensure 
complete deletion and decay of residual proteins. 
 For adipocyte-specific deletion of CrebloxP alleles, CrebloxP/loxP mice were crossed 
with Adipoq-Cre mice (Eguchi et al. 2011; Lee et al. 2013). CrebloxP/loxP mice were used 
as controls. Mice were analyzed between 3 to 5 months of age.  
All the animal care and use procedures followed the guidelines of the Institutional 
Animal Care and Use Committee of the University of Pennsylvania. 
 
Whole Cell Lysate Preparation and Western Blot Analysis 
Tissue fragments were homogenized by hand in 200µL of RIPA buffer containing 
20mmol/l Tris (pH 8.0), 5mmol/l EDTA, 150mmol/l NaCl, 1% TritonX-100, 1% SDS 
and 0.5% deoxycholic acid, supplemented with a protease inhibitor cocktail (Roche), then 
sonicated using a Bioruptor (Diagenode). Whole-cell lysates were centrifuged at 
maximum speed for 15 min to sediment cellular debris, and the supernatant was 
collected. Protein concentrations were measured via Bradford assay using the “Protein 
Assay Reagent” (Bio-Rad). 
Approximately 50µg of whole-cell lysates were separated by SDS-PAGE and 
transferred to nitrocellulose membranes (Invitrogen). Membranes were blocked in buffer 
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containing 5% milk and 0.1% Tween-20 in 1X PBS (milk-PBST) for 30 min, then 
incubated overnight at 4°C with primary antibodies diluted in milk-PBST. After washing, 
membranes were incubated with HRP-conjugated secondary antibodies in milk-PBST for 
1hr at room temperature. Proteins were visualized using the ECL-prime Western Blotting 
Detection System (Amersham GE). 
 
Immunohistochemistry 
Following tissue harvest, tissues were rinsed in phosphate-buffered saline (PBS) 
and fixed in 4% paraformaldehyde overnight, then embedded in paraffin, or 
cryoprotected in 30% sucrose/PBS overnight at 4°C and frozen embedded in OCT and 
frozen. Tissue blocks were sectioned by the CHOP Pathology Core. Sections were 
blocked with normal donkey serum in PBS and incubated with primary antibody at 4°C 
overnight. Fluorophore-conjugated secondary antibodies were applied for 2 h at room 
temperature, and nuclei were stained with DAPI. Hepatocytes were counted using an 
Olympus BG-2 microscope connected to a video camera with a color monitor.  
 
Antibodies 
CREB antibody was purchased from Cell Signaling, USA (#9197). HNF4α 
antibody was purchased from R&D Systems (2ZH1415H). Cyclophilin B was obtained 
from Pierce (PA1-027A). Donkey-anti-rabbit IgG and donkey anti-mouse IgG were 
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obtained from Amersham GE. Cy3-conjucated donkey anti-rabbit secondary antibody 
and Cy5-conjugated donkey anti-mouse secondary antibody were from Jackson 
ImmunoResearch Laboratories) 
 
Glucose Tolerance Test, Insulin Tolerance Test, and Glucagon Stimulation Test 
Glucose tolerance tests were performed on mice fasted for 16hrs; while insulin 
tolerance test and glucagon stimulation test were performed on mice fasted for 3hrs. 
Animals on regular chow were administered 2g/kg body weight glucose, while those on 
the high fat diet were administered 1.5g/kg body weight glucose to prevent glucose 
excursions outside the measurable range. Animals were administered 0.75U/kg body 
weight human insulin (Novo Nordisk), or 16µg/kg body weight glucagon by intra-
peritoneal injection. Blood was sampled from the tail vein at multiple time points and 
glucose levels were measured with a Breeze 2 Glucose Meter (Bayer). 
 
Metabolic Cage Study with Norepinephrine and CL-316,243 Treatment 
 During comprehensive metabolic monitoring, animals were kept at 30°C. 
75mg/kg body weight nembutol was administered for anesthesia. Once mice are sedated, 
animals were given subcutaneous injection of 1mg/kg body weight norepinephrine 
(Sigma Aldrich), or CL-316,243 (Sigma Aldrich). O2 consumption and CO2 production 
were measured, and body heat produced was calculated by indirect calorimetry. 
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Metabolic cage experiments were performed by the Mouse Phenotyping, Physiology and 
Metabolism Core. 
 
CL-316,243 Treatment 
 Animals were moved to 30°C one-week prior to the start of injection, and kept at 
30°C until tissue harvest. Once acclimated to thermoneutrality, animals were injected 
1mg/kg body weight CL-316,243 (Sigma Aldrich) subcutaneously, once a day for 3 days, 
and their tissues were collected 24hrs after the last injection. 
 
Hepatic Lipids, Plasma Lipid and Plasma Adiponectin Measurement 
 Liver fragments were homogenized in PBS. Blood was collected from the tail 
vein after 16hr fasting and 2hr refeeding with lithium-heparin coated microvette 
(Sarstedt). Blood samples were centrifuged for 5 min at 4°C to separate plasma. Hepatic 
triacylglycerol and cholesterol levels were measured via colorimetric assay with Infinity 
triglyceride reagents (Thermo Scientific) and Infinity cholesterol reagents (Thermo 
Scientific). Plasma NEFA, triacylglycerol and β-hydroxybutyrate were measured via 
colorimetric assay with HR Series NEFA-HR (2) kit (Wako Diagnostics), Infinity 
triglyceride reagents (Thermo Scientific) and β-hydroxybutyrate liquicolor kit (Stanbio), 
respectively. Plasma adiponectin levels were measured using an adiponectin ELISA kit 
(Linco). 
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RNA Isolation and Quantitative RT-PCR Analysis 
Total cellular RNA was extracted from tissue fragments using TRIzol (Invitrogen) 
and the RNeasy Kit (Qiagen), according to the manufacturer’s protocol. Approximately 1 
µg of total RNA was reverse transcribed using oligo(dT) and Superscript II Reverse 
Transcriptase (Invitrogen). The resulting cDNA samples were employed as template for 
quantitative RT-PCR experiments performed with Brilliant III Ultra-Fast SYBR QPCR 
Mastermix (Agilent) and the SYBR Green (with dissociation curve) program on the 
Mx300 Multiplex Quantitative PCR System (Stratagene). Reactions were performed in 
triplicate and normalized relative to the ROX reference dye. Median cycle threshold 
values (Ct) were determined and used for analyses. Expression levels were normalized to 
those of hypoxanthine-guanine phosphoribosyltransferase (HPRT) as the internal control. 
Primers are listed in Table 2.1. 
 
mRNA Expression Profiling via Microarray 
RNA isolated from the liver and adipose tissue of overnight-fasted four control 
and four Creb mutant mice, were amplified and labeled using Low-Input Quick Amp 
labeling kits (Agilent). Labeled samples were hybridized overnight to a 4  ×  44 whole 
mouse genome array (Agilent). Arrays were washed and then scanned with the G2565B 
DNA microarray scanner (Agilent). Genes displaying a fold-change over 1.5-fold 
between mutants and controls and a false discovery rate <10%, calculated using 
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significance analysis of microarray analysis (Tusher et al. 2001), were determined as 
significantly changed. Data analysis was prformed by the Functional Genomics Core. 
 
 
 
Primer Sequence (‘5→3’)   
mRNA Fwd Rev 
Cidea TGCTCTTCTGTATCGCCCAGT  GCCGTGTTAAGGAATCTGCTG  
Creb AAGCAGCACGGAAGAGAGAG TTTTCAAGCACTGCCACTCTG 
Crem TGCCTGGTATTCCCAAGATT TTGTATTGCCCCGTGCTAGT 
Dio2 CAGTGTGGTGCACGTCTCCAATC TGAACCAAAGTTGACCACCAG 
Fbpase GCATCGCACAGCTCTATGGT ACAGGTAGCGTAGGACGACT 
G6pase GCAAGGAGACCCAGGATTCTT TGGGCTAGGGAAAGGAGTCAT 
Pepck TGCCCAAGGCAACTTAAGGG CAGTAAACACCCCCATCGCT 
Pgc1α GGTCGAACGAAACTGACTTCG GCAGGGTCAAAATCGTCTGAG 
Pparα GCGTACGGCAATGGCTTTAT GAACGGCTTCCTCAGGTTCTT 
Prdm16 CAGCACGGTGAAGCCATTC  GCGTGCATCCGCTTGTG  
Ucp1 ACTGCCACACCTCCAGTCATT  CTTTGCCTCACTCAGGATTGG  
Table 2.1: List of quantitative RT-PCR primers 
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CHAPTER 3: The Transcription Factor CREB has No Non-
Redundant Function in Hepatic Glucose Metabolism 
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As Published in Diabetologia, June 2014 
3.1 Abstract 
Excessive hepatic glucose production is a hallmark of insulin resistance in type 2 
diabetes.  The cAMP-responsive transcription factor cAMP-responsive element binding 
protein (CREB), thought to be a key activator of the hepatic gluconeogenic gene 
regulation program, has been suggested as therapeutic target to reduce glucose output by 
the liver.  Here, I test directly the requirement for hepatocytic CREB for the maintenance 
of glucose homeostasis. I derived mice with a Creb loxP allele for conditional, cell-type 
specific gene ablation. Hepatocyte-specific deletion of Creb was induced by injecting 
CrebloxP/loxP mice with Cre-expressing adeno-associated virus (AAV-Cre). Strikingly, I 
find no difference in fed and fasted glucose levels, or glucose, insulin, and glucagon 
tolerance in mice fed normal chow or a high-fat diet.  In addition, mRNA levels of liver 
specific genes, including several CREB target genes involved in gluconeogenesis, were 
not affected by CREB deficiency in the liver. In conclusion, my data indicate that CREB 
has no non-redundant functions in hepatic glucose metabolism, and is therefore not likely 
to be a useful target for the development of anti-diabetic drugs. 
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3.2 Introduction 
The cAMP response element binding protein (CREB) is a ubiquitous transcription 
factor that belongs to the basic leucine zipper class (Dwarki et al. 1990). CREB 
contributes to the regulation of genes containing cAMP-responsive elements (CREs) in 
response to changes in cellular cAMP levels. In the liver, key gluconeogenic genes 
contain CREs in their proximal promoters (Zhang et al. 2005; Everett et al. 2013). 
Previous studies suggested that CREB is required for the regulation of gluconeogenesis 
during fasting via recruitment of transcriptional co-activators to cis-regulatory elements 
of relevant genes upon glucagon signaling (Herzig et al. 2001; Zhou et al. 2004; Koo et 
al. 2005; Le Lay et al. 2009). 
Elevated hepatic gluconeogenesis, caused by increased glucagon levels, 
insufficient insulin secretion, and insulin resistance, is the major contributor of fasting 
hyperglycemia in type 2 diabetic patients (DeFronzo et al. 1989; Magnusson et al. 1992; 
Gastaldelli et al. 2000). Despite previous reports implicating inhibition of CREB as a 
means to reduce blood glucose in the liver, the specific requirement for CREB in hepatic 
glucose metabolism has never been addressed, and prior studies on CREB function 
reported conflicting results (Herzig et al. 2001; Herzig et al. 2003; Erion et al. 2009). 
Specifically, there was a significant increase in hepatic triacylglycerol levels in the livers 
of mice expressing acidic-CREB (A-CREB), a dominant-negative inhibitor of CREB 
function, while mice treated with antisense oligonucleotides (ASO) were protected from 
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hepatic steatosis (Herzig et al. 2003; Erion et al. 2009), suggestive of non-specific effects 
of one or both approaches. 
Therefore, to assess the specific role of CREB in the liver in vivo, I employed a 
conditional gene ablation approach. By deleting Creb in adult hepatocytes using Cre 
recombinase expressing adeno-associated virus in CrebloxP/loxP mice, I demonstrate that 
CREB is not required for the regulation of hepatic glucose metabolism. 
 
3.3 Results 
 
3.3.1 Conditional ablation of Creb in hepatocytes 
To assess hepatic CREB function in vivo, a CrebloxP conditional null allele was 
derived via homologous recombination in mouse embryonic stem cells. The targeting 
strategy used to construct this mutant allele is shown in Figure 3.1. loxP sites were 
positioned upstream and downstream of exon 11 to result in deletion of this critical exon 
encoding the DNA binding domain upon exposure to Cre recombinase. In order to obtain 
mice with hepatocyte-specific deletion of Creb, I used an AAV serotype that 
preferentially infects hepatocytes, and controlled expression of Cre recombinase further 
by placing it under the control of the hepatocyte-specific thyroxine-binding globulin 
(Tbg)-promoter (Figure 3.1). Quantitative RT-PCR indicated an 80% decrease in Creb 
mRNA expression in whole liver, consistent with the contribution of hepatocytes to liver 
mass (Figure 3.2a).  Western blotting confirmed the effective reduction of CREB protein 
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levels in the livers of CrebL/L, AAV-Cre mice, with the remaining CREB protein in 
mutant animals stemming from cells other than hepatocytes (Figure 3.2b). In order to 
confirm complete ablation of Creb specifically in hepatocytes, dual label-
immunofluorescence staining with antibodies against the hepatocyte-specific marker 
(HNF4α) and CREB protein (Figure 3.2c, d) were performed.  CREB protein was absent 
from all hepatocytes two weeks post AAV-Cre injection (Figure 3.2e), while Creb 
expression in cholangiocytes and non-paranchymal cells such as stellate and Kupffer 
cells was maintained (Figure 3.2e), indicating 100% efficiency and specificity of the 
AAV-Cre system. 
 
3.3.2 No changes in blood glucose homeostasis in the absence of hepatic Creb 
Since previous studies had suggested that CREB serves as the master regulator of 
gluconeogenesis via transcriptional regulation, I first examined blood glucose levels in 
CrebL/L; AAV-Cre mice and control CrebL/L; AAV-GFP mice after fasting and during 
refeeding.  Surprisingly, there was no difference between blood glucose levels of control 
and Creb-deficient mice (Figure 3.3a). To further analyze the effect of Creb ablation on 
glucose homeostasis, glucose and insulin tolerance tests were performed. In agreement 
with results from fasted and refed glucose measurements, no significant differences 
between control and Creb-null mice were observed in these assays (Figure 3.3b, e). In 
addition, insulin levels during glucose tolerance tests were indistinguishable between the 
two groups (Figure 3.3c). To assess the possibility that CREB’s role in regulating 
gluconeogenesis might be masked by glycogen breakdown during a short-term fast, blood 
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glucose levels were measured during a 72 hour-long starvation period, when hepatic 
gluconeogenesis becomes essential. Strikingly, even during the prolonged fast, 
hepatocyte-specific Creb ablation had no effect on blood glucose levels (Figure 3.3d). 
Thus, CREB is not required in hepatocytes to maintain blood glucose levels. 
 
3.3.3 Ablation of hepatic Creb does not improve insulin sensitivity 
It has been reported that inhibition of CREB activity in the liver leads to 
improvement of hepatic insulin sensitivity in various insulin-resistant rodent models, 
suggesting that CREB might be an attractive therapeutic target for the treatment of type 2 
diabetic patients (Herzig et al. 2001; Erion et al. 2009). To evaluate this possibility, I 
assessed the effects of hepatocyte-specific deletion of Creb on hepatic and peripheral 
insulin sensitivity in the high-fat diet-feeding model. Unlike previous reports employing 
different modes of non-specific CREB inhibition (see discussion), I did not observe 
decreases in blood glucose levels after fasting and during refeeding in Creb-deficient 
mice that had been on a high-fat diet for 10 weeks relative to control mice (Figure 3.4a). 
Because of animals developing insulin resistance after high-fat feeding, I used a smaller 
glucose amount for the studies of high-fat diet fed mice to prevent glucose excursions 
outside the measurable range. There was no improvement in glucose or insulin tolerance 
in high-fat diet fed Creb mutant mice compared to controls (Figure 3.4b, c). To 
investigate the effects of hepatocytic Creb ablation in mediating glucagon signaling and 
activation of the gluconeogenic gene expression program, glucagon stimulation tests 
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were performed. However, loss of hepatocytic Creb did not change post-glucagon blood 
glucose levels compared to controls with intact hepatic Creb (Figure 3.4d). 
 
3.3.4 Loss of Creb does not improve nor aggravate fatty liver condition in insulin-
resistance mice 
Previous studies reported opposite effect of Creb inhibition on fatty liver 
condition. Hepatic lipid accumulation was significantly increased in mice expressing A-
CREB compared to controls (Herzig et al. 2003), while Creb-ASO treatment alleviated 
fatty liver condition by lowering hepatic lipid levels and lipogenic gene expression levels 
(Erion et al. 2009).  To understand the role of Creb in the regulation of hepatic lipid 
accumulation, fatty liver condition was evaluated via histology of high-fat diet fed 
control and hepatocytic Creb mutant mice. H&E (Figure 3.5a, b) and Oil Red O (Figure 
3.5c, d) staining of liver sections revealed no significant alterations in high-fat diet 
induced fatty liver condition in hepatocytic Creb-null mice compared to controls. 
Furthermore, hepatic triglyceride and cholesterol levels were comparable between the 
two groups (Figure 3.5e, f). In addition, loss of Creb in hepatocytes did not change 
circulating lipid levels and alanine transaminase (ALT) levels compared to controls 
(Figure 3.6).  
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3.3.5 Expression of gluconeogenic genes does not change in the absence of 
hepatocytic Creb 
Although there were no physiological changes in hepatocyte-specific Creb null 
mice, I investigated the effect of hepatocytic Creb ablation at the transcriptional level.  
To this end, I harvested livers after an overnight fast to ensure full activation of the 
gluconeogenic gene expression program. Next, mRNA levels of key gluconeogenic genes 
were measured, such as peroxisome proliferator-activated receptor gamma coactivator 1-
alpha (Pgc1α), glucose 6-phosphatase (G6pase), phosphoenolpyruvate carboxykinase 
(Pepck), and fructose bisphosphatase (Fbpase), in regular chow fed (Figure 3.7a) or high-
fat diet fed mice (Figure 3.7b) via quantitative RT-PCR. In contrast to previous studies 
that had reported an 80% decrease in expression levels in mice expressing a dominant-
negative mutant version of CREB relative to controls (Herzig et al., Nature 2001), I did 
not observe any significant changes in steady-state mRNA levels of these gluconeogenic 
genes in hepatocyte-specific Creb null mice (Figure 3.7a and b). To assess effects of 
Creb on entire hepatic transcriptome, expression profiling via microarray was performed 
(Figure 3.7c). Only 21 genes were significantly differentially expressed in Creb-null liver 
compared with controls, none of which are known to function in glucose metabolism 
(Table 3.1). This strongly suggest other factors, including other CREB-family members 
which can also bind to common CRE site, may bind promoters of CREB target genes and 
induce gene expression in the absence of CREB. cAMP-responsive element modulator 
(CREM), another member of CREB family of DNA binding proteins, can also mediate 
transcriptional response to cAMP signaling, and there is some functional redundancy 
between CREB and CREB (Hummler et al. 1994). To determine potential functional 
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compensation by CREM in the absence of CREB, Crem mRNA levels were measured. In 
the livers of hepatocyte specific Creb-null mice, there was a 2-fold increase in Crem 
expression levels, suggesting the regulation of CREB target genes by CREM (Figure 3.8).   
 
3.4 Discussion  
CREB has been established as the master regulator of gluconeogenesis during 
fasting. Multiple studies were performed to determine the role of CREB in the liver by 
utilizing tissue specific dominant-negative (Herzig et al. 2001; Herzig et al. 2003) or 
antisense nucleotide approaches (Erion et al. 2009). Both approaches resulted in 
significant decreases in blood glucose levels, and reduced gluconeogenic gene expression 
in the liver. These results suggested CREB as a potential therapeutic target to improve 
insulin sensitivity in type 2 diabetes patients. However the two approaches reported 
divergent effects on hepatic triacylglycerol metabolism, strongly suggestive of non-
specific effects in one or both models.  The two reports also differed on the proposed 
mediators of hepatic CREB function. Thus, Herzig and colleagues reported that CREB 
regulated hepatic lipid metabolism via peroxisome proliferator-activated receptor gamma 
(PPARγ) (Herzig et al. 2003), while ASO treatment had no effect on PPARγ expression 
levels (Erion et al. 2009).  In addition, these studies neither directly nor specifically 
addressed the role of hepatic CREB due to inherent limitations of the methodologies 
employed. In both studies, CREB activity was suppressed in other tissues as well as the 
liver. In the A-CREB study, expression of CREB was under the control of 
cytomegalovirus (CMV) promoter (Herzig et al. 2001; Herzig et al. 2003), hence no 
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tissue specificity could be achieved. Similarly, Creb-ASO lead to decrease in Creb 
mRNA levels in both the liver and adipose tissue (Erion et al. 2009).  Multiple organs in 
the body control glucose metabolism, and alterations in any of its players can lead to the 
disruption of regulation. For instance, there are suggestions that CREB in the brain might 
be involved in regulation of appetite and food intake (Altarejos et al. 2008; Yadav et al. 
2011; Ren et al. 2013). Therefore it is possible that the blood glucose lowering effect by 
A-CREB or Creb-ASO were due to suppression of CREB in combination of tissues. 
Furthermore, there are well documented off-target effects associated with dominant-
negative CREB mutant proteins (Ahn et al. 1998), while the ASO approach lead to 
decreased Creb mRNA levels in adipose tissue as well as in the liver (Erion et al. 2009). 
In addition, it has been shown that ASO can have biological effects that are not solely 
resulting in specific degradation of their target mRNAs (Woolf et al. 1992; Fisher et al. 
2002).  
To investigate the requirement for CREB in liver metabolism, I utilized the Cre-
loxP system for conditional ablation of Creb in the adult hepatocytes. In my model, I was 
able to confirm complete loss of CREB protein in every hepatocyte post AAV-Cre 
injection, while expression of CREB in non-hepatocytes was maintained. In contrast to 
previous studies suggesting improved insulin sensitivity through inhibition of CREB 
activity via dominant-negative or ASO approach, deletion of hepatocytic Creb had no 
effect on glucose homeostasis and insulin sensitivity. In addition, expression levels of key 
gluconeogenic genes, such as Pgc-1α, G6pase, Pepck and FBPase, in Creb-deficient 
liver were comparable to those of control mice, in contrast to previous studies reporting a 
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50-80% decrease in expression levels following A-CREB overexpression or ASO 
treatment (Herzig et al. 2003; Erion et al. 2009).  In addition, as shown by global 
expression profiling, Creb ablation had insignificant effect on genes involved in hepatic 
metabolism and function, indicating that other factors may bind and regulate CREB 
targets in the absence of CREB. Furthermore, deletion of Creb did not improve insulin 
sensitivity of mice that were fed a high-fat diet to mimic type 2 diabetic conditions. The 
different outcome of CREB deficiency reported here is likely due to the specificity of my 
model system relative to the dominant-negative and ASO approach, which inhibits CREB 
in multiple organs including the liver, and may impact factors other than CREB. My 
results suggest functional redundancy between proteins that bind to CREs as indicated by 
the lack of change in expression levels of CREB target genes in the absence of 
hepatocytic CREB. Partial redundancy among members of mammalian transcription 
factor gene family has been reported previously (Hummler et al. 1994), and an increased 
expression levels of Crem in the hepatocytic Creb-null livers suggests potential 
functional compensation. Nevertheless, these findings put into question the current status 
of CREB as the master regulator of gluconeogenesis and the suitability of specific CREB 
inhibitors as anti-diabetic drugs. 
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Figure 3.1: Design of CrebloxP allele 
loxP sites (white triangles) were positioned to flank the critical exon 11 of the Creb gene. 
Mice harboring the Creb loxP allele were injected with AAV-Cre or AAV-GFP (control). 
In hepatocytes, which are infected by AAV-Cre, removal of exon 11 produces a null 
allele. 
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Figure 3.2: Conditional gene ablation of Creb in hepatocytes 
(a) Quantitative RT-PCR to measure Creb mRNA levels in the liver of Creb L/L mice 
injected with control virus (AAV-GFP; black bar) or AAV-Cre (white bar). Transcription 
levels in Creb L/L; AAV-GFP mice were set to 1. N  =  5 for each group. Values are 
presented as average ± SE. *p  <  0.005. (b) Western blot analysis of whole-cell liver 
lysates taken from livers of Creb L/L mice injected with AAV-GFP or AAV-Cre as 
indicated. HNF4α was used as loading control. (c and d) Liver sections from mice of 
indicated genotypes were stained with antibody against CREB (red) and HNF4α (green). 
Only HNF4α− non-parenchymal cells maintain CREB expression (yellow arrowheads) in 
Creb L/L; AAV-Cre livers. (e) Percentage of CREB+ hepatocytes (HNF4α+ cells) in 
control (AAV-GFP injected; black bar) or mutant (AAV-Cre injected; white bar) liver. 
n  =  3 for each group. *p  <  0.005. 
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Figure 3.3: Mice lacking Creb in hepatocytes maintain normal glucose homeostasis 
(a) Blood glucose levels of control (Creb L/L; AAV-GFP) and hepatocyte-specific Creb 
mutant mice (Creb L/L; AAV-Cre) after 24 h fasting (0 time point) and during re-feeding 
at the times indicated. N  =  5–6 for each group. (b) Blood glucose levels and (c) insulin 
levels of control and Creb-deficient mice after overnight fasting (0 min) and following 
injection of a glucose bolus (2 g/kg body weight) at the times indicated. N  =  5-6 for each 
group. (d) Blood glucose levels of control and Creb-deficient mice after 3 h fasting (0 
min) and following an insulin injection at the times indicated. n  =  5 for each group. (e) 
Blood glucose levels of control and Creb-deficient mice during the course of 72 h fast. 
N  =  4 for each group. Black squares, Creb L/L; AAV-GFP. White diamonds, Creb L/L; 
AAV-Cre. 
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Figure 3.4: Deletion of hepatocytic Creb does not improve glucose homeostasis of 
high-fat diet fed mice 
(a) Blood glucose levels of high-fat diet fed control (Creb L/L; AAV-GFP) and 
hepatocyte-specific Creb-null mice (Creb L/L; AAV-Cre) after 24 h fasting (0 time point) 
and during re-feeding at the times indicated. N  =  9 for each group. (b) Blood glucose 
levels of high-fat diet fed control and Creb-deficient mice after overnight fast (0 time 
point) and following injection of a glucose bolus (1.5 g/kg body weight) at the times 
indicated. N  =  15 for each group. (c) Blood glucose levels of high-fat diet fed control and 
Creb mutant mice after 3 h fasting (0 time point) and following an insulin injection at the 
times indicated. N  =  6–7 for each group. (d) Blood glucose levels of high-fat diet control 
and Creb-deficient mice after 3 h fasting (0 time point) and following a glucagon 
injection at the times indicated. n  =  5 for each group. Black squares, Creb L/L; AAV-GFP. 
White diamonds, Creb L/L; AAV-Cre. 
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Figure 3.5: Deletion of hepatocytic Creb does not improve fatty liver of high-fat diet 
fed mice 
(a and b) H&E staining of liver sections from mice of indicated genotypes (c and d) Liver 
sections from mice of indicated genotypes were stained with Oil Red O visualization of 
neutral triglycerides and lipids. Quantitative measurement of triglyceride (e) and 
Cholesterol (f) levels in high-fat diet fed control (Creb L/L; AAV-GFP; black bar) or 
mutant (Creb L/L; AAV-Cre; white bar) livers. Values are presented as average ± SE. 
n=11 for each group. 
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Figure 3.6: Loss of CREB in hepatocytes does not change plasma lipid profiles 
To determine lipid profiles in circulations, plasma triglyceride (a), non-esterified fatty 
acids (NEFA; b), phospholipid (c), high-density lipoprotein (HDL; d), cholesterol (e), 
and non-HDL-cholesterol (f) levels were measured in high-fat diet fed control (AAV-
GFP injected; black bar) or mutant (AAV-Cre injected; white bar) mice. In addition, 
Plasma alanine transaminase (ALT; g) levels were measured to detect liver injury. Values 
are presented as average ± SE. n=7 for each group. 
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Figure 3.7: Loss of CREB in hepatocytes does not change gluconeogenic gene 
expression 
(a) Quantitative RT-PCR to measure mRNA levels of Pgc1α, G6pase, Pepck and Fbpase 
in the liver of control and liver-specific Creb mutant mice after an overnight fast. n  =  5–6 
for each group. (b) Quantitative RT-PCR to measure relative mRNA levels of Pgc1α, 
G6pase, Pepck and Fbpase in the liver of high-fat fed control and hepatocyte-specific 
Creb-deficient mice after an overnight fast. n  =  5–6 for each group. Transcription levels 
of control mice were set to 1. Values are presented as average ± SE. Black bar, Creb L/L; 
AAV-GFP. White bar, Creb L/L; AAV-Cre. (c) MA-plot of Creb L/L; AAV-GFP liver 
RNA vs. Creb L/L; AAV-Cre liver RNA from regular chow diet fed mice after an 
overnight fast. The M-axis is the log2 fold-change between the two groups, while the A-
axis denotes the log2 average intensity in the two groups. Each point represents a gene 
(grey), and significantly differentially expressed genes (10% false discovery rate, >1.5-
fold change) are marked in black. The dashed line indicates median M value for all 
points. 
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Figure 3.8: Crem expression levels were increased by 2-fold in the livers of mice 
lacking hepatocytic Creb 
Quantitative RT-PCR to measure mRNA levels of Crem in iWAT and BAT of control 
and adipocyte-specific Creb-null mice. Black bar, Creb L/L; AAV-GFP. White bar, Creb 
L/L; AAV-Cre. Transcription levels in CrebL/L mice were set to 1. Values are presented as 
average ± SE. *p < 0.05. n = 5–6 for each group. 
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Gene Name Description Fold 
Change 
Mup20 major urinary protein 20 2.136 
Moxd1 monooxygenase, DBH-like 1 1.915 
NAP112258-1 major urinary protein, pseudogene 10 1.846 
Cyp2c55 cytochrome P450, family 2, subfamily c, polypeptide 55 1.705 
A_55_P2144090 major urinary protein, pseudogene 3 1.69 
Tceal8 transcription elongation factor A (SII)-like 8 -1.592 
Olfr1229 olfactory receptor 1229 -1.592 
1700013B16Rik RIKEN cDNA 1700013B16 gene -1.595 
Clpx caseinolytic peptidase X (E.coli) -1.631 
Gpr137b G protein-coupled receptor 137B -1.88 
Ttc37 tetratricopeptide repeat domain 37 -2.141 
Mfsd6 major facilitator superfamily domain containing 6 -2.342 
E130012A19Rik RIKEN cDNA E130012A19 gene -2.41 
Neat1 nuclear paraspeckle assembly transcript 1 (non-protein 
coding) 
-2.564 
Camk2n2 calcium/calmodulin-dependent protein kinase II inhibitor 2 -2.674 
Tmem215 transmembrane protein 215 -2.703 
Kif4b kinesin family member 4B -3.165 
Cntn4 contactin 4 -3.322 
Krtap5-5 keratin associated protein 5-5 -5.348 
2310065F04Rik RIKEN cDNA 2310065F04 gene -7.042 
Ren1 renin 1 structural -15.152 
   
Table 3.1: Significantly differentially expressed genes in hepatocyte specific Creb-
null liver 
	  	  53 
CHAPTER 4: Adipocytic CREB Regulates Fasting-Induced 
Lipolysis but Has No Non-Redundant Function in 
Thermogenesis 
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4.1 Abstract 
Lipolysis and thermogenesis are regulated by catecholamines signaling via β-
adrenergic receptors in adipose tissue. Previous studies suggested a role for the cAMP-
responsive transcription factor cAMP-responsive element binding protein (CREB) in 
adipocyte function, but this hypothesis was never functionally confirmed by an adipose-
specific ablation of Creb in vivo. Here, I test directly the requirement for adipocyte 
CREB for lipolysis and thermogenesis using the Cre-loxP system for adipocyte-specific 
ablation of Creb in mice. Loss of adipocytic Creb lead to a moderate decrease in fasting-
induced lipolysis in adipose tissue. Strikingly, the adipocytic transcriptome was not 
globally affected by ablation of Creb. In addition, cold temperature and cAMP signaling-
induced thermogenesis and white-to-beige adipocyte conversion were not changed in 
adipocyte specific Creb-null mice compared to controls. In conclusion, my data indicate 
that CREB has no non-redundant functions in thermogenesis, but contributes to the 
regulation of fasting-induced lipolysis. The underlying mechanism of reduced fasting-
induced lipolysis in adipocytic CREB-deficient mice will need to be explored further. 
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4.2 Introduction 
Adipose tissue is an active metabolic organ, in which excess energy is stored for 
use in times of food deprivation in the form of lipids. In addition, adipose tissue also 
provides protection and insulation for internal organs, generates body heat, and 
communicates with other organs via adipose-derived hormones. The two types of 
adipocytes that comprise the majority of adipose tissue are white adipocytes and brown 
adipocytes. Unilocular white adipocytes store energy in the form of large single lipid 
droplets in their cytoplasm. Unlike white adipocytes, multilocular brown adipocytes carry 
fat in multiple small lipid droplets, and also contain numerous mitochondria, which give 
brown fat its dark color. The main function of brown adipocytes is thermogenesis in 
response to cold exposure. (Rothwell and Stock 1979; Rothwell et al. 1982).  Brown 
adipocytes express uncoupling protein-1 (UCP1) in the inner membranes of 
mitochondria, which assist heat production by uncoupling oxidative phosphorylation 
from electron transport. Prolonged exposure to low temperature or catecholamine 
signaling results in the transformation of subpopulations of white adipocytes into beige 
adipocytes that expresses UCP1 (Young et al. 1984; Cousin et al. 1992; Petrovic et al. 
2010). 
There are multiple adipose depots in the body. The major fat depots are 
abdominal subcutaneous white adipose tissue, visceral white adipose tissue, and 
subclavicular/subscapular brown adipose tissue. (Frühbeck 2008; Bjorndal et al. 2011; 
Cinti 2012).  Both white adipose tissue (WAT) and brown adipose tissue (BAT) are 
innervated by sympathetic nerve endings (Cottle and Cottle 1970; Bowers et al. 2004; 
Bartness et al. 2010). Lipolysis and thermogenesis are regulated by catecholamine 
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signaling via β-adrenergic receptors (Landsberg et al. 1984; Carpéné et al. 1998). Binding 
of the catecholamine norepinephrine to β3-adrenergic receptors on brown and white 
adipocytes leads to increased cytoplasmic cAMP levels, which activate protein kinase A 
(PKA). PKA phosphorylates hormone-sensitive lipase (HSL), and activated HSL 
hydrolyzes lipid triacylglycerols in lipid droplets, releasing glycerol and fatty acids. In 
brown adipocytes, released fatty acids activate UCP1, in addition to acting as substrates 
for oxidative phosphorylation. 
Although all adipose depots play a role in buffering energy imbalance, metabolic 
rates can vary among the depots. For example, visceral white fat is more metabolically 
active than subcutaneous white fat, contributing more to circulating free fatty acid levels 
(Wajchenberg 2000; Hajer et al. 2008). Due to the difference in lipolytic rates, visceral 
fat contributes more in development of metabolic syndrome and type 2 diabetes mellitus 
(T2DM) relative to the other depots (Bjorndal et al. 2011). Furthermore, white adipocytes 
in inguinal subcutaneous WAT are more susceptible to beige transformation than those in 
epididymal WAT, even though all white fat depots express Ucp1 upon cold exposure or 
catecholamine treatment. (Himms-Hagen et al. 2000; Barbatelli et al. 2010; Vitali et al. 
2012; Wu et al. 2012; Harms and Seale 2013).  
Recently, BAT has received increased attention recently due to its implications as 
a potential target for the treatment of obesity (Lockie et al. 2013; Mund and Frishman 
2013; Chechi et al. 2014).  In rodents, ablation of BAT or UCP1 leads to obesity due to 
loss of diet-induced thermogenesis (Lowell et al. 1993; Feldmann et al. 2009). Similarly, 
chronic treatment with a β3-adrenergic receptor-specific agonist reverses obesity and 
insulin-resistance in rodents (Ghorbani et al. 1997; Ghorbani and Himms-Hagen 1997; 
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Liu et al. 1998). These data suggest that heat production from BAT is a critical regulator 
of whole body energy metabolism. In humans, presence of BAT in adults has only been 
recognized recently (Hany et al. 2002; Yeung et al. 2003). Some studies have indicated 
an inverse correlation between body mass index and BAT activity (Cypess et al. 2009; 
Saito et al. 2009; van Marken Lichtenbelt et al. 2009). Therefore, BAT activity can 
potentially contribute to energy expenditure in adult humans. Furthermore, molecular 
characteristics of human brown adipocytes are similar to that of murine beige adipocytes 
rather than brown adipocytes (Wu et al. 2006). Thus, stimulants that induce ‘browning’ 
of white adipose tissue may be useful in treating obesity and diabetes in humans. 
 cAMP response element-binding protein (CREB) is a transcription factor that 
binds to cAMP response elements (CREs) in cis-regulatory regions, and mediates cAMP 
effects on transcriptional regulation. In adipocytes, β3- adrenergic signaling can activate 
CREB (Chaudhry and Granneman 1999; Thonberg et al. 2002). In a previous study, 
obese mice expressing a dominant-negative CREB specifically in brown and white 
adipocytes displayed improved insulin sensitivity, and were protected from adipose tissue 
inflammation (Qi et al. 2009). In addition, CREB-regulated transcription coactivator 3 
(CRTC3) was shown to promote obesity by attenuating β-adrenergic receptor signaling in 
adipose tissue (Song et al. 2010). The proximal promoter region of the mouse Ucp1 gene 
contains CRE half-sites along with other cis-regulatory elements (Kozak et al. 1994; Rim 
and Kozak 2002), suggesting possible direct regulation of its expression by CREB. In 
fact, cold-stimulated Ucp1 levels in beige adipocytes were higher in the A/J strain of 
mice compared to that of the obesity-prone C57BL/6J strain, and correlated with higher 
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activation of CREB (Xue et al. 2005). Furthermore, adipocytic CREB has been shown to 
regulate cAMP-induced expression of peroxisome proliferator-activated receptor- γ 
coactivator-1α (Pgc1α) (Karamanlidis et al. 2007; Karamitri et al. 2009), which enhances 
Ucp1 expression during cold-induced thermogenesis. Therefore, I investigated the role of 
CREB in adipose tissue, taking advantage of the Cre-LoxP cell type specific gene 
ablation approach. I hypothesized that loss of CREB in adipose tissue would lead to a 
decrease in lipolysis and thermogenesis. In my study, loss of adipocytic CREB leads to a 
moderate decrease in adipose tissue lipolysis. After subsequent evaluation of BAT 
activation and β3-adrenergic receptor specific agonist-induced browning of white 
adipocytes, I demonstrate that CREB is not required for the regulation of thermogenesis. 
 
4.3 Results 
 
4.3.1 Ablation of CREB in Adipose Tissue does not affect body composition and 
adipocyte morphology 
To assess adipocytic CREB function in vivo, I crossed homozygous CrebloxP mice 
(Lee et al. 2014) with Adipoq-Cre mice, which expresses Cre recombinase in adipocytes 
(Eguchi et al. 2011; Lee et al. 2013). Quantitative RT-PCR confirmed an ~80% decrease 
in Creb mRNA levels in both inguinal WAT (iWAT) and interscapular BAT of 
CrebloxP/loxP; Adipoq-Cre mice (Figure 4.1a).  Effective reduction in CREB protein levels 
in iWAT and BAT was confirmed by western blotting (Figure 4.1b). 
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Body composition was determined using nuclear magnetic resonance (NMR), and 
calculated as percentage lean and fat mass of total body weight for both the control and 
adipocyte-specific CREB-null mice. Body weights were comparable between the two 
groups, with similar lean to fat mass ratios, indicating that loss of adipocytic CREB did 
not affect overall body composition (Figure 4.2). Furthermore, there were also no 
significant difference in the histology of iWAT and BAT of adipocytic CREB-null mice 
relative to controls (Figure 4.3). 
 
4.3.2 Loss of CREB in adipose tissue decreases fasting plasma fatty acid levels  
 During fasting, glucagon and catecholamine induce lipolysis in adipose tissue to 
release fatty acids and glycerol, which are utilized in peripheral tissues for energy 
production. To investigate the role of CREB in lipolysis, I measured circulating lipid 
levels in control and adipocyte-specific CREB-null mice during fasting and refeeding. 
Interestingly, while plasma triacylglycerol levels and ketone body levels were unchanged, 
fasting plasma non-esterified fatty acids (NEFA) levels were 40% lower in CrebloxP/loxP; 
Adipoq-Cre mice compared to controls (Figure 4.4a, c, and d), indicating defects in 
fasting-induced lipolysis.  
 Adiponectin is an adipose tissue secreted hormone involved in the regulation of 
glucose and fatty acid metabolism. In adipose tissue, adiponectin facilitates lipid uptake 
and inhibits lipolysis (Kim et al. 2007; Qiao et al. 2011; Wedellová et al. 2011).  In a 
previous study, inhibition of adipocytic CREB using a dominant-negative approach led to 
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an increase in circulating adiponectin levels (Qi et al. 2009). I measured circulating 
adiponectin levels to determine if loss of adipocytic CREB had any effect on adiponectin 
secretion in my model. Plasma adiponectin levels of adipocyte-specific CREB-null mice 
were comparable to those of control mice (Figure 4.4b). 
 To assess the involvement of CREB in the adipocyte transcriptome, I performed 
expression profiling via microarray in epididymal WAT isolated from both adipocytic 
Creb-null mice and controls that were fasted overnight. Surprisingly, loss of CREB had 
no effect on WAT gene expression and only a single gene, TAF-6-like RNA Polymerase 
II, p300/CBP-associated factor (PCAF)-associated factor (Taf6l), was found to be 
differentially expressed between CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre (Table 4.1). 
Despite a 10-fold increase in expression levels, currently there is no known function for 
taf6l in lipid metabolism. Thus, the underlying mechanism of reduced fasting-induced 
lipolysis in adipocytic CREB-deficient mice it is still unclear, and further studies need to 
be performed to address this issue. 
 
4.3.3 Ablation of adipocytic Creb does not affect BAT activity 
Although loss of Creb in adipose tissue did not affect the morphology of BAT, I 
nevertheless investigated if Creb deficiency affected thermogenesis. To evaluate cold-
induced thermogenesis, mice were kept at 4°C for 3 hours, and the core temperature was 
measured every 30 minutes. There were no appreciable differences in the changes of core 
temperature between CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre mice (Figure 4.5). 
Because mice are able to maintain their core temperature via shivering as well as by 
	  	  61 
thermogenesis, I wanted to further determine and confirm the degree of BAT activation 
in adipocytic Creb-null mice.  
 To remove any shivering effects, I utilized pharmacological reagents to induce 
BAT activation. In vivo, BAT thermogenesis is activated by norepinephrine from the 
sympathetic nervous system (Landsberg et al. 1984). Mice were anesthetized and kept at 
30°C, within the mouse thermoneutrality zone, during the course of the experiment to 
exclude shivering-induced thermogenesis. Norepinephrine-induced heat production was 
calculated by measuring CO2 production and O2 consumption. At the basal state, heat 
production was not significantly different between control mice and adipocyte-specific 
CREB mutants (Figure 4.6). Treatment with subcutaneous injection of norepinephrine 
increased body heat production by 5-fold in both control and mutant animals, and both 
the CO2 production and the O2 consumption were comparable between the two groups 
(Figure 4.6). These results indicate that loss of Creb has no effect on norepinephrine-
induced thermogenesis. 
 In brown adipocytes, the effect of norepinephrine is carried out by β3-adrenergic 
receptors coupled to the cAMP-signaling pathway (Cannon et al. 1996). However, it is 
important to note that norepinephrine also targets the liver and skeletal muscle as well as 
adipose tissue. Since β3-adrenergic receptors are mainly present in adipose tissue, I 
decided to repeat the above experiment using the highly selective β3-adrenergic receptor 
agonist CL-316,243, to eliminate any potential influence of other tissues on heat 
production. CL-316,243 was previously demonstrated to increase energy expenditure by 
activating thermogenesis in BAT (Grujic et al. 1997). Overall, the effects of CL-316,243 
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on CO2 production and O2 consumption were similar to those of norepinephrine, and loss 
of CREB had no effect on CL 316,243-induced heat production (Figure 4.7). This 
suggests CREB is not required for β3-adrenergic receptor-mediated thermogenesis by 
BAT. 
 
4.3.4 CREB is not required for CL-316,243-induced thermogenic gene expression. 
Prolonged exposures to cold temperatures or treatment with β3-adrenergic 
receptor agonists, promotes the transformation of subpopulations of white adipocytes into 
beige adipocytes that express Ucp1 (Young et al. 1984; Cousin et al. 1992; Petrovic et al. 
2010). Ucp1 contains CRE half-sites in its proximal promoter region (Kozak et al. 1994; 
Rim and Kozak 2002), and CREB can potentially regulate its expression during white-to-
beige transformation at the transcriptional level. To further test the role of CREB in this 
process, both adipocytic CREB-null and control mice were kept within thermoneutrality 
and treated with CL-316,243 for 3 days. BAT and iWAT were harvested, and quantitative 
PR-PCR was performed to determine the expression levels of BAT identity genes and 
thermogenic genes. As expected, CL-316,243 treatment increased expression of 
thermogenic genes such as Ucp1, Pgc-1α, and type II iodothyronine deiodinase (Dio2) in 
BAT (Figure 4.8a). Loss of CREB did not have any effect on expression of BAT identity 
genes (Figure 4.8b). In iWAT, CL-316,243 treatment increased expression of Ucp1, 
indicating the presence of beige adipocytes (Figure 4.9a). Absence of CREB had no 
significant impact on CL-316,243-induced expression of thermogenic genes in iWAT 
(Figure 4.9a). As reported previously, expression levels of Cidea were increased in 
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iWAT after CL-316,243 (Figure 4.9b). However, the expression levels of BAT identity 
genes were similar between control and CREB-null cells (Figure 4.9b). These results 
indicate that both the transcriptional regulation of thermogenic genes by the cAMP 
signaling pathway and the browning of white adipocytes do not require CREB. 
 
4.4 Discussion  
 Previous studies suggested a role for CREB in adipocyte function, but this 
hypothesis was never functionally confirmed by an adipose-specific ablation of Creb in 
vivo. Inhibition of CREB reduced inflammations in adipose tissue and increased secretion 
of adiponectin in mice expressing adipocytic A-CREB (Qi et al. 2009). However, there 
are well documented off-target effects associated with dominant-negative CREB mutant 
proteins (Ahn et al. 1998). Thus it is possible that the inhibition of combinations of 
proteins by dimerization with A-CREBs lead to the observed phenotype in the study 
above.  Furthermore, a role for CREB in the regulation of thermogenesis and 
development of beige adipocytes, had been suggested based on enhanced CREB 
expression and activation in brown adipocytes upon rise in intracellular cAMP levels 
(Chaudhry and Granneman 1999; Thonberg et al. 2002), and CREB’s observed ability to 
regulate the expression of Pgc1α and Ucp1 (Kozak et al. 1994; Nedergaard et al. 2001; 
Rim and Kozak 2002). However, none of above studies investigated the requirement of 
CREB in thermogenesis. 
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To directly evaluate the requirement of CREB in lipolysis and thermogenesis, I 
utilized the Cre-loxP system for adipocyte specific ablation of Creb in mice. Loss of 
adipocytic CREB did not affect body weight or composition. BAT and iWAT of adipose 
tissue-specific CREB mutant had normal histology compared to controls. Interestingly, 
fasting-induced lipolysis was reduced in adipocytic CREB-null mice, but there were no 
alterations in circulating adiponectin levels. Expression analysis of global RNA levels in 
white adipose tissue did not reveal any potential mechanism underling the suppression of 
lipolysis in mice lacking adipocytic CREB. This might be explained in part by the fact 
that only a subpopulation of adipocytes in white adipose tissue undergoes lipolysis upon 
catecholamine signaling and that this changes in gene expression in a subset of 
adipocytes are masked by the bulk of unresponsive cells. To address this issue, future 
experiments will examine the effect of loss of CREB on lipolysis and lipolytic gene 
expression in vitro using primary adipocytes.  
In regards to CREB’s role in thermogenesis, CrebloxP/loxP; Adipoq-Cre mice had 
similar cold tolerance as the control mice. BAT activation was further tested by treatment 
with norepinephrine and β3-adrenergic agonist CL-316,243. Despite the suggestions from 
previous studies, loss of CREB had no effect on thermogenesis. Furthermore, expression 
levels of Ucp1 and Pgc1α in adipocytic CREB-null BAT and iWAT were comparable to 
those of controls in both saline and CL-316,243 treated animals, suggesting proteins 
besides CREB can also bind to cis-regulatory elements in thermogenic genes containing 
CREs, and regulate their expression. Partial functional redundancy exists between the 
CREB/AFT family members that share dimerization domain and kinase-inducible 
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domain with CREB (Hummler et al. 1994), and they may be able to dimerize and recruit 
other transcription factors to promoters of target genes in the absence of CREB. This 
study thoroughly examined the role of CREB in thermogenesis at both the physiological 
and molecular levels, and I conclude that there are no non-redundant functions of CREB 
in the cAMP-mediated activation of thermogenesis and the white-to-beige adipocyte 
transformation, while it regulates fasting-induced lipolysis through an as of yet unknown 
mechanism. 
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Figure 4.1: Creb ablation in adipocytes 
(a) Quantitative RT-PCR to determine Creb mRNA levels in iWAT and BAT. 
Transcription levels in CrebL/L mice in each tissue were set to 1. Values are presented as 
the average ± SE. *p < 0.005. n = 7–8 for each group. (b) Western blot analysis of whole-
cell lysates confirms loss of CREB in mutant CrebL/L; Adipoq-Cre mice in both iWAT 
and BAT of control and mutant mice as indicated. Cyclophilin B was used as a loading 
control. 
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Figure 4.2: Loss of CREB does not affect body composition 
Body weight and nuclear magnetic resonance (NMR) analysis to determine the percent 
lean mass and percent fat mass of control (CrebL/L) and mutant (CrebL/L; Adipoq-Cre) 
mice. Values are presented as the average ± SE. n=7–8 in each group.  
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Figure 4.3: Creb-null iWAT and BAT displayed normal adipocyte morphology 
H&E staining of iWAT and BAT isolated from both control (CrebL/L) and mutant 
(CrebL/L; Adipoq-Cre) mice. 
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Figure 4.4: Reduction of fasting plasma non-esterified fatty acids (NEFA) levels in 
adipocytic CREB-null mice 
Circulating NEFA (a), adiponectin (b), triacylglyceride (c), and β-hydroxybutyrate (d) 
levels were measured. Fasted plasma was collected after 16hr fasting, and refed plasma 
was collected after 2hr refeeding. Values are presented as average ± SE. n=17–18 in each 
group.  
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Figure 4.5: Response to cold exposure was not affected by the loss of adipocytic 
CREB 
Core temperature measurements of Crebloxp/loxp and Crebloxp/loxp; Adipoq-Cre mice during 
3 hour exposure to 4°C. Values are presented as the average ± SE. n=4-5 for each group. 
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Figure 4.6: Adipocytic CREB-null mice exhibited similar norepinephrine (NE)-
induced thermogenesis 
O2 consumption and CO2 production were measured before and after NE injection. Heat 
production was calculated via indirect calorimetry. Mice were kept under anesthesia and  
at 30°C during the experiment. Values are presented as the average ± SE. n=3–4 for each 
group. 
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Figure 4.7: CL-316,243-induced thermogenesis of adipocyte specific CREB mutant 
mice was similar to controls 
CL-316,243 is a β3-adrenergic receptor agonist. O2 consumption and CO2 production was 
measured before and after CL-316,243 injection. Heat production was calculated via 
indirect calorimetry. Mice were kept under anesthesia and at 30°C during the experiment. 
Values are presented as the average ± SE. n=4–7 for each group. 
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Figure 4.8: CL-316,243-induced expression levels of thermogenic genes in BAT of 
adipocytic CREB-null mice were similar to those of controls 
(a) Quantitative RT-PCR to measure mRNA levels of Ucp1, Pgc1α, and Dio2 in the BAT 
of control and adipocyte-specific adipocytic Creb mutant mice after 3-day injection with 
saline or CL-316,243. n  =  9–12 for each group. (b) Quantitative RT-PCR to measure 
relative mRNA levels of Prdm16, Pparα and Cidea in BAT of control and adipocyte-
specific Creb-deficient mice after saline or CL-316,243 treatment for 3 days. 
Transcription levels of control mice were set to 1. Values are presented as the average ± 
SE. n  =  9–12 for each group. 
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Figure 4.9: Similar expression levels of thermogenic and BAT identity genes in 
inguinal WAT (iWAT) of adipocytic Creb-null mice compared to controls 
(a) Quantitative RT-PCR to measure mRNA levels of Ucp1, Pgc1α, and Dio2 in the 
iWAT of control (CrebL/L) and adipocyte-specific Creb mutant (CrebL/L; Adipoq-Cre) 
mice after 3-day injection with saline or CL-316,243. n  =  9–12 for each group. (b) 
Quantitative RT-PCR to measure relative mRNA levels of Prdm16, Pparα and Cidea in 
iWAT of control and adipocyte-specific Creb-deficient mice after saline or CL-316,243 
treatment for 3 days. Transcription levels of control mice were set to 1. Values are 
presented as the average ± SE. n  =  9–12 for each group. 
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Gene Name Description Fold 
Change 
Taf6l TAF-6-like RNA Polymerase II, p300/CBP-associated 
factor (PCAF)-associated factor 
10.79 
 
Table 4.1: A Single gene was significantly differentially expressed in adipocyte 
specific Creb-null eWAT  
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CHAPTER 5: Thesis Summary and Future Directions 
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5.1  Thesis Summary 
 In this thesis, I investigated of the role of the transcription factor CREB in the 
function of the liver and adipose tissue. Initially, I evaluated the role of hepatic CREB in 
glucose homeostasis and insulin sensitivity. Previous studies described CREB as the 
central regulator of the gluconeogenesis in the liver (Herzig et al. 2001; Erion et al. 2009). 
In those studies, inhibition of CREB activity reduced blood glucose levels and improved 
whole-body insulin sensitivity in rodent models of diabetes and insulin resistance, 
suggesting CREB as a potential therapeutic target to reduce hyperglycemia in T2DM 
patients. However, those studies utilized approaches that did not specifically target 
hepatocytic CREB. Therefore, I employed the Cre-loxP system to specifically determine 
the role of CREB in the regulation of hepatic glucose metabolism in Chapter III.  
Contrary to the previous understanding of CREB function, I report that glucose 
homeostasis was unaffected in mice conditionally deficient for Creb in the hepatocyte 
lineage (CrebL/L; AAV-Cre). In addition, loss of hepatocytic CREB did not improve 
insulin sensitivity in mice fed a high fat diet. Indeed, gluconeogenic gene expression 
levels in hepatocytic Creb mutants were comparable to those of controls. Therefore, 
CREB has no non-redundant function in hepatic glucose metabolism. My data questions 
previous understanding of CREB and its suggested role in regulation of gluconeogenesis, 
and thus CREB is not a plausible therapeutic target to treat T2DM.  
 Secondly, I investigated the role of CREB in the regulation of lipolysis and 
thermogenesis in adipose tissue. Previous reports suggested CREB as a mediator for 
cAMP-effects on transcriptional regulation of lipogenic and thermogenic genes by 
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directly binding to their cis-regulatory regions (Kozak et al. 1994; Rim and Kozak 2002; 
Karamanlidis et al. 2007; Karamitri et al. 2009). However despite these suggestions, the 
function of CREB in adipocytes had never been directly evaluated. To assess adipocytic 
CREB function in vivo, I crossed homozygous CrebloxP mice (Lee et al. 2014) with 
Adipoq-Cre mice, which expresses Cre recombinase in adipocytes (Eguchi et al. 2011; 
Lee et al. 2013). In Chapter IV, I report data on the effect of Creb ablation in the 
regulation of lipolysis and thermogenesis in adipose tissue. Body composition and 
adipocyte morphology in adipocyte-specific Creb-null (CrebloxP/loxP; Adipoq-Cre) mice 
were comparable to controls. Interestingly, fasting-induced lipolysis was moderately 
decreased in adipocytic Creb-null mice. Previous studies reported reduced 
catecholamine-induced lipolysis in obese subjects compared to non-obese subjects 
(Jensen et al. 1989; Bougneres et al. 1997; Langin et al. 2005). My data suggest CREB is 
required for fasting-induced lipolysis and dysfunction of CREB may contribute to the 
development of obesity. However, the expression profiling of epididymal WAT using 
microarray did not reveal potential CREB target genes that may affect lipolysis. Hence, 
the underlying mechanism of reduced fasting-induced lipolysis in adipocytic CREB-
deficient mice it is still unclear, and further studies need to be performed to address this 
issue. 
The understanding of CREB function in the liver and adipose tissue prior to this 
work was largely based upon studies that utilized a dominant-negative inhibitor of CREB 
(A-CREB) (Herzig et al. 2001; Herzig et al. 2003; Qi et al. 2009) or an antisense 
oligonucleotide (ASO) approach (Erion et al. 2009). A key shortcoming of these studies 
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is the lack of tissue specificity. CREB is a ubiquitously expressed transcription factor that 
serves various functions in different tissues. Therefore, inhibition of CREB activity in 
multiple metabolic tissues may lead to dysregulation of whole-body metabolism, making 
it harder to determine the tissue-specific role of CREB in the regulation of metabolism. 
Furthermore, the A-CREB dominant-negative model can inhibit other basic leucine 
zipper proteins in addition to CREB. In the A-CREB protein, an acidic amphipathic 
protein sequence replaces the CREB basic region connected to the N-terminus of the 
dimerization domain, allowing it to form a heterodimer with endogenous CREB protein, 
and prevents CREB binding to DNA (Ahn et al. 1998). Since the other members of the 
CREB/ATF share a conserved dimerization domain with CREB (Hummler et al. 1994), it 
is possible for A-CREB to inhibit these related proteins as well. Likewise, A-CREB may 
also bind to other basic leucine zipper proteins such as CCAAT/enhancer-binding protein 
beta (C/EBPβ), which dimerizes with CREB to bind CRE half-sites in Ucp1 gene 
(Karamanlidis et al. 2007; Karamitri et al. 2009).  The results of this thesis highlight the 
importance of re-evaluating previously suggested drug targets for human disease, and 
caution must to be taken when interpreting metabolic findings from mouse models with 
ill-defined molecular manipulations. 
 
5.2 Future Directions 
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5.2.1 Functional redundancy among CREB, activating cAMP-responsive element 
modulator (CREM) and transcription factor-1 (ATF1) in the regulation of 
hepatic glucose metabolism 
In Chapter III, I used conditional gene ablation to show that the transcription 
factor Creb has no non-redundant function in hepatic glucose metabolism. In the absence 
of hepatocytic CREB, there no changes in expression levels of proposed CREB target 
genes, which I suggest was due to functional redundancy between members of the 
CREB/ATF protein family. At least two additional members of the CREB/ATF family, 
namely CREM and ATF1, can also mediate transcriptional responses to cAMP signaling 
(Hurst and Jones 1987; Hai et al. 1988; Philippe and Missotten 1990; Hummler et al. 
1994). These three CREB family members also share a conserved dimerization domain 
and kinase-inducible domain, suggesting partial functional redundancy. Indeed, CREM 
and ATF1 are capable of dimerizing with CREB as well as CREB, and all of which are 
targeted by PKA for phosphorylation (Hummler et al. 1994).  
In Chapter III, I observed a two-fold increase in Crem mRNA and protein levels 
in the livers of CrebloxP/loxP;AAV-Cre mice. Therefore, absence of changes in blood 
glucose levels and gluconeogenic gene expression in hepatocyte-specific Creb-null mice 
is likely explained by functional compensation by CREM. Similar hypothesis can be 
proposed with Aft1, if Atf1 expression levels in the livers of hepatocytic Creb-deficient 
mice as well. 
The above hypothesis could be further investigated by chromatin 
immunoprecipitation sequencing (ChIP-Seq) to determine if CREM and ATF1 bind to 
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CREB target genes in the absence of CREB. Comparison of these ChIP-Seq data to 
existing genome-wide CREB-binding data (Everett et al. 2013) may also reveal specific 
subclasses of CREB target genes are bound and regulated by CREM and ATF1. If CREM 
and/or ATF1 bind to gluconeogenic genes in the absence of CREB, as I hypothesize, the 
next step will be to generate mice with hepatocyte-specific ablation of Creb, Crem and 
Atf1. First, mice carry loxP flanked alleles of Crem and Atf1will be generated and these 
mice will be bred together with existing CrebloxP/loxP to generate CrebloxP/loxP; CremloxP/loxP 
Atf1loxP/loxPmice. Hepatocyte-specific deletion of loxP-flanked alleles can be achieved by 
injection of AAV-Cre, as I demonstrated in Chapter III. Evaluating glucose metabolism 
and insulin resistance in these mice will complete the analysis of transcriptional 
regulation of glucose homeostasis by the cAMP-responsive transcription factors in the 
liver, and their impact on the regulation of blood glucose levels.  
Genome-wide CREB-binding data revealed CREB binding at lipid metabolism 
genes (Everett et al. 2013). However, previous studies reported contradicting effects of 
CREB inhibition on the accumulation of lipid in the liver (Herzig et al. 2003; Erion et al. 
2009).  In Chapter III, I demonstrated that ablation of hepatocytic Creb alone does not 
improve nor aggravate fatty liver condition in high-fat diet fed, insulin-resistance mice, 
and this could be also due to potential functional compensation by CREM and ATF1. 
Therefore, the evaluation of hepatic and circulating lipid levels in CrebloxP/loxP; 
CremloxP/loxP; Atf1loxP/loxP; AAV-Cre mice is of particular importance, in order to 
understand if the CREB family of DNA binding proteins plays a role in the regulation of 
hepatic lipid metabolism.  
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5.2.2 Mechanism underlying reduced fasting-induced lipogenesis in adipocytic 
Creb-null mice 
In Chapter IV, I demonstrated that CREB plays a role in the regulation of 
lipolysis during fasting with adipocyte-specific deletion of Creb using Cre-loxP system. 
However, transcriptome analysis of epididymal WAT by microarray expression profiling 
did not reveal any potential mechanism underlying the suppression of lipolysis in mice 
lacking adipocytic CREB. The absence of significantly differentially expressed genes in 
the above analyses can be explained in part by the fact that only a subpopulation of 
adipocytes in white adipose tissue undergoes lipolysis upon catecholamine signaling. It is 
also possible that the microarray platform was not sensitive enough to detect small 
changes in gene expression; this could overcome by the more sensitive RNA sequencing-
based expression analysis. 
 To address these issues, primary preadipocytes isolated from mouse adipose 
tissue will be differentiated in vitro to determine changes in lipolytic gene expression in 
response to β-adrenergic signaling.  Treating adipocytes with β-adrenergic agonist in 
vitro will ensure induction of lipolysis in all cells. Mammalian preadipocyte 
differentiation can be achieved in vitro with IDX cocktail, composed of insulin, 
dexamethasone, and isobutylmethylxanthine (IBMX) (Green and Meuth 1974; Russell 
and Ho 1976; Student et al. 1980).  In preadipocytes, insulin signals through insulin 
growth factor-1 (IGF1) receptor to activate the adipogenic cascade (Rosen and 
MacDougald 2006). Dexamethasone treatment activates the glucocorticoid signaling 
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pathway which regulates adipocyte differentiation (Chapman et al. 1985), and IBMX 
increases intracellular cAMP levels by inhibiting soluble cyclic nucleotide (Elks and 
Manganiello 1985).  
 I previously isolated primary preadipocytes from inguinal WAT (iWAT) of 
CrebloxP/loxP; Adipoq-Cre mice, and differentiated them in vitro by addition of the IDX 
cocktail. However, Creb was not deleted in differentiated adipocytes from CrebloxP/loxP; 
Adipoq-Cre mice. Although Adipoq promoter should be active post-differentiation, it was 
identified that Adipoq-Cre is not efficient in deleting loxP-flanked alleles in vitro. 
Therefore, I am currently isolating primary preadipocytes from iWATs of CrebloxP/loxP 
mice, and they will be differentiated into mature white adipocytes in the culture using 
IDX cocktail. Ablation of Creb will be achieved by transfecting differentiated 
CrebloxP/loxP primary preadipocytes with Cre-mRNA. CrebloxP/loxP cells transfected with 
eGFP-mRNA will be used as controls. The cells will be treated with norepinephrine to 
induce lipolysis, relative levels of lipolysis between Cre-mRNA and eGFP-mRNA 
transfected adipocytes will be determined by measuring glycerol levels in collected 
media. Cells will also be harvested for RNA, and quantitative RT-PCR will be performed 
to determine and compare expression levels of lipolysis genes between Cre-mRNA and 
eGFP-mRNA transfected-CrebL/L primary white adipocytes. If significantly differentially 
expressed genes are identified, CREB binding at the promoters of these genes will be 
determined by cross-referencing genome-wide CREB-binding data that I obtained 
previously via chromatin-immunoprecipitation sequencing (ChIP-Seq) on white adipose 
tissue. 
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5.2.3 The role of adipocytic CREB in the development of insulin-resistance and 
obesity 
In humans, fat tissues from obese individuals are resistant to catecholamine-
induced lipolysis when compared to those of non-obese subjects (Jensen et al. 1989; 
Bougneres et al. 1997; Langin et al. 2005). In Chapter IV, I demonstrated decreased 
fasting-induced lipolysis in regular chow fed Creb-null mice. My results reinforce the 
importance of understanding adipocytic CREB’s role in metabolic dysregulation, and 
suggest CREB have therapeutic potential for treatment of obesity. The diet-induced 
obesity model employed in Chapter III can be applied to CrebloxP/loxP; Adipoq-Cre mice to 
study the function of Creb and lipolysis in the context of obesity and insulin-resistance. 
Body composition, energy expenditure, and circulating lipid levels will be evaluated to 
determine if ablation of Creb accelerates the development of obesity.  In addition, 
catecholamine-induced lipolysis can be evaluated in vitro using fat biopsies from 
CrebloxP/loxP and CrebloxP/loxP; Adipoq-Cre mice. Should the role of CREB in the 
development of obesity be confirmed in rodents, expression levels of Creb mRNA and 
protein should be measured in fat biopsies from and obese and non-obese human subjects 
to further validate CREB as a potential therapeutic target for obesity.  
 
Although mice are commonly used in basic research to model human diseases, 
many pharmacological agents that work well in mice turn out to be ineffective in humans. 
Therefore, both similarities and differences between the mouse models of obesity and 
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obesity in humans must be thoroughly investigated before any serious consideration of 
mouse-model based targets can be used in human drug and therapeutic development.  
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